NCT06259071Recruiting
MuSK Myasthenia 1000 Study
Genome Wide Association Study of Patients With Muscle Specific Kinase Myasthenia Gravis
Source: ClinicalTrials.gov · Last updated 5 Aug 2026
Brief summary (registry, in English)
The MuSK myasthenia gravis 1000 study seeks to collect saliva samples from 1000 subjects with laboratory confirmed diagnosis of MuSK myasthenia to identify genetic variations associated with MuSK MG. The data collected may be used by researchers to gain a better understanding of the cause of MuSK MG and to identify biomarkers and targeted therapy for MuSK MG.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 1000 (estimated)
- First submitted
- 6 Feb 2024
- Start date
- 23 Aug 2023
- Primary completion date
- 23 Aug 2027
- Lead sponsor
- George Washington University
- Diseases
- Myasthenia gravis
- NCT number
- NCT06259071
What you commit to
- Study type: Observational
- Planned participants: 1000
- From 23 Aug 2023 to the primary completion date, 23 Aug 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Unwillingness to provide lab results of elevated muscle specific kinase antibody
Other
- Inability to provide informed consent
- Unwillingness to provide saliva sample
Who the study is looking for
- Lab test confirming diagnosis of MuSK myasthenia gravis
- Willingness to provide saliva sample via mail or in person
Age in the registry: 7 years to 99 years · Sex: All
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| George Washington University Coordinator of this site? Confirm its status | Washington D.C. | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.